Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All News Releases
        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Hamburger menu
    • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
    • Create a Free Account
      • ALL CONTACT INFO
      • Contact Us


        11AM ET Sunday – 8PM ET Friday

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Why PRWeb
    • Contact
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022


      News provided by

      Research Advisor at Reportbuyer.com

      Nov 25, 2013, 13:15 ET

      Share this article

      Share this article


      London (PRWEB) November 25, 2013 -- PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

      Summary

      GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

      GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.

      Scope

      -Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
      -Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
      -Sales forecast for the top drugs in the US from 2012-2022.
      -Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.

      Reasons to buy

      -Understand and capitalize by identifying products that are most likely to ensure a robust return
      -Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
      -Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
      -Make more informed business decisions from insightful and in-depth analysis of drug performance
      -Obtain sales forecast for drugs from 2012-2022 in the US

      Table of Contents

      1 Table of Contents 4
      1.1 List of Tables 7
      1.2 List of Figures 8
      2 Introduction 9
      2.1 Catalyst 9
      2.2 Related Reports 10
      3 Disease Overview 12
      3.1 Etiology and Pathophysiology 12
      3.1.1 Etiology 12
      3.1.2 Pathophysiology 14
      3.2 Symptoms 15
      3.3 Prognosis 16
      4 Disease Management 17
      4.1 Meningococcal Immunization Policy 18
      4.2 US 20
      4.2.1 Meningococcal Immunization Recommendations and Policies 20
      4.2.2 Clinical Practice 22
      5 Competitive Assessment 25
      5.1 Overview 25
      5.2 Strategic Competitor Assessment 25
      5.3 Product Profiles – Major Brands 27
      5.3.1 Menactra 27
      5.3.2 Menveo 31
      5.3.3 MenHibrix 34
      5.3.4 Menomune 37
      6 Opportunity and Unmet Need 41
      6.1 Overview 41
      6.2 Unmet Needs 42
      6.2.1 Unmet Need: Protection Against Serogroup B Disease 42
      6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine 43
      6.2.3 Unmet Need: More Cost-Effective Vaccines 44
      6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents 45
      6.2.5 Unmet Need: Immunogenic Infant Vaccines 46
      6.2.6 Unmet Need: Improved Vaccination Coverage Rates 47
      6.2.7 Unmet Need: Increased Patient Awareness and Education 48
      6.3 Unmet Needs Gap Analysis 49
      6.4 Opportunities 49
      6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations 49
      6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants 50
      6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets 51
      7 Pipeline Assessment 52
      7.1 Overview 52
      7.2 Promising Vaccines in Clinical Development 53
      7.2.1 MnB rLP2086 55
      7.3 Promising Vaccines in Early Clinical Development 60
      8 Market Outlook 61
      8.1 United States 61
      8.1.1 Forecast 61
      8.1.2 Key Events 65
      8.1.3 Drivers and Barriers 66
      9 Appendix 70
      9.1 Bibliography 70
      9.2 Abbreviations 80
      9.3 Methodology 82
      9.4 Forecasting Methodology 82
      9.4.1 Vaccine Coverage 83
      9.4.2 Vaccine Approval vs. Routine Schedule Inclusion 83
      9.4.3 Vaccines Included 84
      9.4.4 Key Launch Dates 85
      9.4.5 General Pricing Assumptions 86
      9.4.6 Individual Vaccine Assumptions 86
      9.4.7 Pricing of Pipeline agents 88
      9.5 Physicians and Specialists Included in this Study 89
      9.6 About the Authors 92
      9.6.1 Authors 92
      9.6.2 Reviewers 92
      9.6.3 Global Head of Healthcare 93
      9.7 About GlobalData 94
      9.8 Disclaimer 94

      List of Tables

      Table 1: Symptoms of Meningococcal Disease 16
      Table 2: Meningococcal Immunization Recommendation Agencies by Country 18
      Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 19
      Table 4: Leading Vaccines for Meningococcal Disease, 2012 26
      Table 5: Product Profile – Menactra 28
      Table 6: Menactra SWOT Analysis, 2012 30
      Table 7: Product Profile – Menveo 32
      Table 8: Menveo SWOT Analysis, 2012 34
      Table 9: Product Profile – MenHibrix 35
      Table 10: MenHibrix SWOT Analysis, 2012 37
      Table 11: Product Profile – Menomune 38
      Table 12: Menomune SWOT Analysis, 2012 40
      Table 13: Overall Unmet Needs – Current Level of Attainment 41
      Table 14: Clinical Unmet Needs – Gap Analysis, 2012 49
      Table 15: Meningococcal Vaccines – Phase Pipeline, 2012 54
      Table 16: Comparison of Vaccines in Development for Meningococcal Disease, 2012 55
      Table 17: Product Profile – MnB rLP2086 56
      Table 18: MnB rLP2086 SWOT Analysis, 2012 59
      Table 19: Sales Forecasts ($m) for Meningococcal Vaccines in the United States, 2012–2022 63
      Table 20: Key Events Impacting Sales for Meningococcal Vaccines in US, 2012 65
      Table 21: United States Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022 66
      Table 22: Key Launch Dates 85
      Table 23: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 91

      List of Figures

      Figure 1: Membrane Structure of N. meningitidis 13
      Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Meningococcal Vaccines, 2012–2022 54
      Figure 3: Sales for Meningococcal Vaccines in the United States by Vaccine Class, 2012–2022 64

      Read the full report:

      PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

      http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_meningococcal_vaccines_us_drug_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

      For more information:
      Sarah Smith
      Research Advisor at Reportbuyer.com
      Email: [email protected]
      Tel: +44 208 816 85 48
      Website: http://www.reportbuyer.com/

      Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]

      Modal title

      Contact PRWeb

      • 11AM ET Sunday – 8PM ET Friday
      • Contact Us

      About PRWeb

      • About PRWeb
      • Partners
      • Partnership Programs
      • Editorial Guidelines
      • Resources

      Why PRWeb

      • Why PRWeb
      • How It Works
      • Who Uses It
      • Pricing

      Accounts

      • Create a Free Account
      • Log in
      • Contact Us

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Online Member Center
      • ProfNet
      Cision Distribution Helpline
      888-776-0942
      • Legal
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 Cision US Inc.